Table 2 Treatment response to nivolumab
From: Low-dose nivolumab in advanced hepatocellular carcinoma
|  | All patients (n = 78) | Nivolumab 20 mg (n = 17) | Nivolumab 100 mg (n = 61) | P value | Nivolumab second line (n = 45) | Nivolumab third and later lines (n = 33) | P value |
|---|---|---|---|---|---|---|---|
Partial response | 4 (5.1%) | 1 (5.9%) | 3 (4.9%) | 0.65 | 4 (8.9%) | 0 (0%) | 0.17 |
Stable disease | 21 (26.9%) | 6 (35.3%) | 15 (24.6%) | Â | 13 (28.9%) | 8 (24.2%) | Â |
Progressive disease | 53 (68.0%) | 10 (58.8%) | 43 (70.5%) | Â | 28 (62.2%) | 25 (75.8%) | Â |
Disease control rate | 25 (32.0%) | 7 (41.2%) | 18 (29.5%) | Â | 17 (37.8%) | 8 (24.2%) | Â |